• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Coherus BioSciences Reports Q3 2024 Financials & Updates

    GLOBENEWSWIRE

    Coherus to Report Q3 2024 Financial Results on November 6, 2024

    GLOBENEWSWIRE

    Coherus`s Loqtorzi (toripalimab) Receives Approval in Europe

    EMA

    Coherus Faces Biosimilar Supply Issues Due To Manufacturer Problems

    FIERCE PHARMA

    Coherus BioSciences Reports Q2 2024 Results And Business Update

    GLOBENEWSWIRE

    Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

    GLOBENEWSWIRE

    Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh)

    GLOBENEWSWIRE

    What Coherus` $40M sale of its Humira biosimilar says about the crowded market

    ENDPOINTS

    Junshi, Coherus move Loqtorzi closer to another approval

    FIERCE PHARMA

    Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

    GLOBENEWSWIRE

    Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Coherus Oncology Summit Presence: Cowen Insights Asco Eha Featured

    GLOBENEWSWIRE

    Coherus Phase I Anti-Ccr8: Chs-114 Preliminary At 2024 Asco

    GLOBENEWSWIRE

    Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

    GLOBENEWSWIRE

    Coherus BioSciences Q1 2024 Financials And Business Update

    GLOBENEWSWIRE

    Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

    GLOBENEWSWIRE

    Coherus to Present at ASCO 2024 Annual Meeting

    GLOBENEWSWIRE

    Coherus Biosciences` Loqtorzi (toripalimab) Receives Suppl. Approval in the U.S.

    FDA

    Coherus Presents Data for CHS-1000 at the 2024 AACR

    GLOBENEWSWIRE

    Coherus` new focus on oncology leads to restructuring, 30% layoffs

    ENDPTS

    Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Coherus lays off 30% of employees amid new ‘sharpened focus’

    FIERCE PHARMA

    Coherus to Report Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Sandoz acquires CIMERLI® business from Coherus

    GLOBENEWSWIRE

    Coherus Completes Divestiture of Ophthalmology Franchise

    GLOBENEWSWIRE

    Coherus BioSciences Announces New Employment Inducement Grants

    GLOBENEWSWIRE

    Coherus Announces U.S. Launch of UDENYCA ONBODY

    GLOBENEWSWIRE

    Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

    GLOBENEWSWIRE

    Sandoz announces agreement to acquire CIMERLI® business from Coherus

    GLOBENEWSWIRE

    Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M

    FIERCE PHARMA

    Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug

    GLOBENEWSWIRE

    Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyout

    ENDPTS

    INOVIO and Coherus Announce Clinical Collaboration

    PR NEWSWIRE

    Coherus Management to Present at 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Coherus Announces U.S. Launch of LOQTORZI„¢

    GLOBENEWSWIRE

    Coherus Announces FDA Approval of UDENYCA ONBODY™

    GLOBENEWSWIRE

    Coherus BioSciences Announces New Employment Inducement Grants

    GLOBENEWSWIRE

    Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

    GLOBENEWSWIRE

    Coherus BioSciences Announces CFO Transition Plans

    GLOBENEWSWIRE

    Coherus Presents Phase 1/2 Clinical Data on Casdozokitug

    GLOBENEWSWIRE

    Coherus and Junshi Bio Announce Publication of Positive Results of LOQTORZI

    GLOBENEWSWIRE

    Coherus prices China-made PD-1 at 20% discount to Keytruda

    FIERCE PHARMA

    Coherus BioSciences Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Coherus Presents Data from Next-generation Immuno-oncology Programs

    GLOBENEWSWIRE

    Coherus BioSciences to Participate at Upcoming November Investor Conferences

    GLOBENEWSWIRE

    Coherus to Report Third Quarter 2023 Financial Results on November 6, 2023

    GLOBENEWSWIRE

    Coherus spurns `heavily discounted` pricing for new PD-1 med

    FIERCE PHARMA

    Coherus Biosciences` Biologic Loqtorzi (toripalimab) Receives Approval in the U.S.

    FDA

    Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI

    GLOBENEWSWIRE

    Coherus BioSciences Announces New Employment Inducement Grants

    GLOBENEWSWIRE

    Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC Conference

    GLOBENEWSWIRE

    Coherus Announces Resubmission of BLA Supplement for UDENYCA® ONBODY

    GLOBENEWSWIRE

    CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

    GLOBENEWSWIRE

    Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

    GLOBENEWSWIRE

    Coherus Announces Three Presentations at the 38th Annual Meeting of SITC

    GLOBENEWSWIRE

    Coherus hits pair of FDA hurdles

    FIERCE PHARMA

    Coherus BioSciences Announces New Employment Inducement Grants

    GLOBENEWSWIRE

    Coherus` Biologic Yusimry (Adalimumab) Receives Approval in the U.S.

    FDA

    Coherus Completes Surface Oncology Acquisition

    GLOBENEWSWIRE

    Coherus BioSciences to Participate at Upcoming September Investor Conferences

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.